The Icatibant Outcome Survey: treatment of laryngeal angioedema attacks

Eur J Emerg Med. 2016 Jun;23(3):224-7. doi: 10.1097/MEJ.0000000000000292.


Objective: To characterize the management and outcomes of life-threatening laryngeal attacks of hereditary angioedema (HAE) treated with icatibant in the observational Icatibant Outcome Survey (NCT01034969) registry.

Methods: This retrospective analysis was based on data from patients with HAE type I/II who received healthcare professional-administered or self-administered icatibant to treat laryngeal attacks between September 2008 and May 2013.

Results: Twenty centers in seven countries contributed data. Overall, 42 patients with HAE experienced 67 icatibant-treated laryngeal attacks. Icatibant was self-administered for 62.3% of attacks (healthcare professional-administered, 37.7%). One icatibant injection was used for 87.9% of attacks, with rescue or concomitant medication used for 9.0%. The median time to treatment was 2.0 h (n=31 attacks) and the median time to resolution was 6.0 h (n=35 attacks).

Conclusions: This analysis describes successful use of icatibant for the treatment of laryngeal HAE attacks in a real-world setting.

Publication types

  • Multicenter Study
  • Observational Study

MeSH terms

  • Angioedemas, Hereditary / drug therapy*
  • Anti-Inflammatory Agents, Non-Steroidal / administration & dosage
  • Anti-Inflammatory Agents, Non-Steroidal / therapeutic use*
  • Bradykinin / administration & dosage
  • Bradykinin / analogs & derivatives*
  • Bradykinin / therapeutic use
  • Female
  • Hereditary Angioedema Types I and II / drug therapy
  • Humans
  • Injections, Subcutaneous
  • Laryngeal Diseases / drug therapy*
  • Male
  • Retrospective Studies
  • Surveys and Questionnaires
  • Treatment Outcome


  • Anti-Inflammatory Agents, Non-Steroidal
  • icatibant
  • Bradykinin

Associated data